Clarient, Definiens Partner on Image Analysis for Cancer Biomarkers | GenomeWeb
NEW YORK (GenomeWeb News) – Imaging company Definiens and the cancer treatment technology company Clarient have agreed to co-develop tools for evaluating cancer biomarkers, Clarient said today.
 
Under the terms of the five-year agreement, the companies will develop a series of image analysis tools that Clarient will use in its internal research programs and will also offer through its PathSite customer web portal.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.